A market gap and innovative treatment concept raise interest in new anti-thrombotic drugs

11 November, 2019

Thrombosis is the most common cause of death globally, as one in four deaths are related to it. For decades, the pharmaceutical industry has worked to create better anti-thrombotic treatments in order to optimise the balance between thrombosis prevention and the risk of bleeding, a commitment that is now beginning to pay off both in terms of research advancements and ability to attract commercial interest. At the centre of this development is Swedish Cereno Scientific with a potentially groundbreaking pipeline.

Read the full article on BioStock here.